GE Healthcare this week released results from a pair of studies researching use of its MultiOmyx protein detection system in lymphoma and breast cancer.

The studies comprised an assessment of the company's nine-protein Hodgkin Lymphoma Profile assay, which it launched in July through its Clarient Diagnostic Services division, and an exploratory research effort using the system to evaluate known prognostic biomarkers in breast cancer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.